MedinCell SA
http://www.medincell.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MedinCell SA
Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
Teva Prepares To Launch LAI Risperidone After US Approval
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
MPP Teams Up With MedinCell For Investigational Malaria Transmission Treatment
The Medicines Patent Pool has secured a licensing deal with MedinCell for a long-acting injectable ivermectin drug formulation which could be used to prevent ongoing spread of malaria.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice